Newsletter | July 29, 2021

07.29.21 -- Technologies And Advancements In Vaccine Manufacturing Platforms

 
Optimizing Downstream Processing For An Inactivated Rabies Vaccine
 

This application note describes the improvements made to the downstream portion of the process, specifically, the use of single-use technologies and novel techniques for clarification and ultrafiltration/diafiltration, and it establishes a rapid, scalable, and GMP compliant process.

Adenoviral Vector Vaccine: Single-Use Manufacturing Process
 

This new poster demonstrates how a GMP transferable process for adenovirus vector-based vaccines manufacturing was successfully developed with Jenner Institute.

Plasmid DNA Downstream Process For Gene Therapy And Vaccine Development
 

Plasmid DNA (pDNA) has become an important therapeutic modality in the form of DNA vaccines and as the basis for RNA vaccines and gene therapy vectors. Purification of pDNA for use as vaccine doses, however, presents several challenges. This application note presents a comprehensive set of technologies that are available to optimize the entire workflow.

Foot And Mouth Disease (FMD) Virus Vaccine: Filtration Strategies For Optimal Development And Purification
 

This white paper illustrates a collaboration with MEVAC to optimize the filtration strategies used during both upstream and downstream processing of foot and mouth disease (FMD) virus vaccine to ensure scalable, cost-effective, and robust GMP-compliant manufacturing.

What Technologies Should You Apply To Your Vaccine-Specific Process?
 

Because there are many pathogens, there are also many vaccines. They can be classified by antigen character, but the manufacturing flows used to produce them are relatively similar. Learn more about how vaccines have been protecting against disease since the late 1700s, and how they function by triggering the immune system to generate short-term and long-term responses.